Health

Source link : https://newshealth.biz/health-news/high-dx-yield-supports-workup-for-inoca/ Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%. Medscape Medical News Source link : https://www.medscape.com/viewarticle/comprehensive-workup-yields-diagnosis-most-nonobstructive-2026a10009je?src=rss Author : Publish date : 2026-03-29 19:23:00 Copyright for syndicated content belongs to the linked Source. The post High Dx Yield Supports Workup for INOCA first […] More

Source link : https://newshealth.biz/health-news/resistant-dermatomyositis-improves-quickly-significantly-with-combination-drug/ DENVER — Treatment-resistant dermatomyositis improved significantly with the investigational TYK2/JAK1 inhibitor brepocitinib, according to a randomized trial. The higher of two doses of brepocitinib improved the total dermatomyositis score by almost 50% at 1 year as compared with placebo. The novel therapy demonstrated superiority over placebo across all nine secondary endpoints, including skin disease, glucocorticoid […] […] More

Source link : https://newshealth.biz/health-news/pcks9s-seen-driving-down-ldl-c-in-diabetes/ A subgroup analysis of the VASALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis. Medscape Medical News Source link : https://www.medscape.com/viewarticle/pcks9s-seen-driving-down-ldl-c-diabetes-2026a10009jb?src=rss Author : Publish date : 2026-03-29 18:16:00 Copyright for syndicated content belongs to the linked Source. The post PCKS9s Seen Driving Down LDL-C in […] More

Source link : https://newshealth.biz/health-news/upadacitinib-significantly-improves-vitiligo-vs-placebo/ The JAK1 inhibitor in development for treating nonsegmental vitiligo was superior to placebo on investigator ratings in two phase 3 trials. Medscape Medical News Source link : https://www.medscape.com/viewarticle/upadacitinib-results-significant-improvements-nonsegmental-2026a10009j2?src=rss Author : Publish date : 2026-03-29 17:23:00 Copyright for syndicated content belongs to the linked Source. The post Upadacitinib Significantly Improves Vitiligo vs Placebo first appeared on News […] More

Source link : https://newshealth.biz/health-news/dermatomyositis-targeted-drug-shows-promise-vs-placebo/ At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments. Medscape Medical News Source link : https://www.medscape.com/viewarticle/dermatomyositis-targeted-drug-shows-promise-vs-placebo-2026a10009iz?src=rss Author : Publish date : 2026-03-29 16:39:00 Copyright for syndicated content belongs to the linked Source. The post Dermatomyositis: Targeted Drug Shows Promise vs […] More

Source link : https://newshealth.biz/health-news/my-patients-are-asking-for-leucovorin-heres-what-i-tell-them/ When the White House announced it was exploring leucovorin as a treatment for autism, the calls from families started pouring in: “Can you prescribe leucovorin for my child?” We experience versions of this frequently: an unproven treatment gains momentum on social media, and we as physicians must become informed enough to counsel families who are […] […] More

Source link : https://newshealth.biz/health-news/active-surveillance-for-dcis-moves-closer-to-standard-option-but-not-quite-there/ Women who opted for active surveillance (AS) for ductal carcinoma in situ (DCIS) had ipsilateral invasive breast cancer survival (iiBCS) similar to patients who had immediate surgery, a randomized trial showed. After a total follow-up of about 4 years, iiBCS favored AS at 24 months (94.3% vs 90.6%) and met statistical criteria for non-inferiority at […] […] More

Source link : https://newshealth.biz/health-news/complement-inhibitor-slowed-kidney-decline-in-iga-nephropathy/ Iptacopan significantly slowed kidney function decline over 24 months compared with placebo in adults with IgA nephropathy. The complement inhibitor was granted accelerated approved in 2024; continued approval was contingent on demonstrating slowed kidney decline. Fewer participants in the iptacopan group reached the composite kidney-failure endpoint. Iptacopan (Fabhalta) slowed kidney function decline in adults with […] […] More

Source link : https://newshealth.biz/health-news/hi-peitho-kicks-off-golden-era-in-pulmonary-embolism/ NEW ORLEANS — A major advance for the treatment of intermediate-risk pulmonary embolism (PE) arrived with HI-PEITHO’s landmark report on ultrasound-facilitated, catheter-directed thrombolysis (CDT). In this hard-to-treat group of acute PE patients, the composite endpoint of PE-related death, cardiorespiratory decompensation or collapse, or symptomatic recurrence of PE within 7 days significantly favored individuals who got […] […] More

Source link : https://newshealth.biz/health-news/pcsk9-drug-prevents-first-heart-events-in-diabetes-patients-without-atherosclerosis/ NEW ORLEANS — Evolocumab (Repatha) reduced risk of a first major cardiovascular (CV) event in patients with diabetes but no known atherosclerosis in a substudy of the VESALIUS-CV trial. The PCSK9 inhibitor cut relative risk by 31% compared with placebo whether looking at the composite of death from coronary heart disease, myocardial infarction (MI), or […] […] More

Source link : https://newshealth.biz/health-news/watchman-laa-occluder-bounces-back-as-alternative-to-oac-in-champion-af/ NEW ORLEANS — It may be reasonable for people with atrial fibrillation (Afib) to undergo percutaneous left atrial appendage (LAA) closure even if long-term anticoagulation is an alternative, according to the large CHAMPION-AF trial presented here. Three years after LAA closure with the Watchman FLX device, statistical criteria were met for the device’s non-inferiority to […] […] More

Source link : https://newshealth.biz/health-news/fibrinolytic-beats-current-standard-for-intermediate-risk-pe/ For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy. Medscape Medical News Source link : https://www.medscape.com/viewarticle/fibrinolysis-treatment-validated-large-trial-acute-2026a10009im?src=rss Author : Publish date : 2026-03-28 21:20:00 Copyright for syndicated content belongs to the linked Source. The post Fibrinolytic Beats Current Standard for Intermediate-Risk PE first appeared […] More